Eryhtropoietin-Free Hemodialysis Patients: Is Chronic Hepatitis an Extra Advantage? | Zendy

Ayşegül Zumrutdal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Eryhtropoietin-Free Hemodialysis Patients: Is Chronic Hepatitis an Extra Advantage?

Author(s) -

Ayşegül Zumrutdal

Publication year - 2011

Publication title -

nephrology research and reviews

Language(s) - English

Resource type - Journals

ISSN - 2035-813X

DOI - 10.4081/nr.2011.e7

Subject(s) - hemodialysis , medicine , erythropoietin , hbsag , gastroenterology , hemoglobin , hepatitis , hepatitis a virus , chronic hepatitis , hepatitis b , kidney disease , immunology , hepatitis b virus , virus

This study aimed to compare the erythropoietin- independent hemodialysis patients who had hepatitis with those who did not. Hemodialysis patients with or without hepatitis who were able to maintain nearly normal hemoglobin levels of 12 g/dL or over, without the administration of recombinant human erythropoietin for at least one year were analyzed retrospectively. Forty-three of the 534 hepatitis-negative hemodialysis patients (8%) and 20 (8 with HbsAg, 12 with HCV) of the 79 hemodialysis patients with hepatitis (25.3%) did not need erythropoietin therapy for one year. Only 9 of the patients were female (male 85.7%). Time on hemodialysis therapy was statistically longer in patients with hepatitis (77.8±42.2 vs. 123.6±51.1 months, P=0.001). There were 30 patients with acquired cystic kidney disease (47.6%) and there was no difference between hepatitis positive and negative patients (P>0.05). Chronic hepatitis infection was significantly associated with EPO independency (P= 0.003). In this study, male gender, more years on hemodialysis therapy and chronic hepatitis seem to be possible factors contributing to normal hemoglobin levels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research